Opioid Treatment Programs

Here is the updated information for Opioid Treatment Programs for your patients during COVID-19:

In updated guidance, CMS notes that periodic assessments can be furnished during the PHE via two-way interactive audio-video communication technology; in addition, in cases where beneficiaries do not have access to two way audio-video communications technology, the periodic assessments may be furnished using audio-only telephone calls rather than via two-way interactive audio-video communication technology, provided all other applicable requirements are met.

For more information:

Note that the new Interim Final Rule provides the following is a list of resources posted on the Substance Abuse and Mental Health Services Administration (SAMHSA) website:

• Opioid Treatment Program (OTP) Guidance (March 16, 2020) available at

• OTP Guidance for Patients Quarantined at Home with the Coronavirus available at

• FAQs: Provision of Methadone and Buprenorphine for the Treatment of Opioid Use

Disorder in the COVID-19 Emergency available at

• COVID-19 Public Health Emergency Response and 42 CFR Part 2 Guidance

available at

• Considerations for the Care and Treatment of Mental and Substance Use Disorders in the COVID-19 Epidemic: March 20, 2020 available at

3 views0 comments

Recent Posts

See All

Medicare Open Enrollment Begins Today!

Open enrollment for Medicare health and drug plans began today! Now is a wonderful opportunity to encourage your patients who are currently enrolled in Medicare Advantage and/or prescription drug plan

COVID-19 Booster Billing Codes Issued

The National Community Pharmacists Association (NCPA) has updated its COVID-19 vaccine billing and reimbursement handout to reflect the changes in the National Council for Prescription Drug Programs'